Related Experiment Video
Updated: Apr 25, 2026
Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
WS0701: a novel sedative-hypnotic agent acting on the adenosine system
Xiao-Yu Bai1, Xue-Qiong Zhang, Yong-He Zhang
1aBeijing Key Laboratory of Drug Targets Identification and Drug Screening bState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of New Drug Research and Development, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College cDepartment of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing dWeifang Traditional Chinese Medicine Hospital, Shan Dong, China.
The novel adenosine derivative WS0701 demonstrates anxiolytic and sedative effects, influencing sleep stages by increasing slow-wave sleep. Its actions are linked to the adenosine system.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Adenosine plays a crucial role in regulating sleep and anxiety.
- Novel compounds targeting the adenosine system are being investigated for therapeutic potential.
Purpose of the Study:
- To characterize the sedative, hypnotic, and anxiolytic profile of the novel adenosine derivative WS0701.
- To investigate the influence of WS0701 on sleep architecture and its mechanism of action.
Main Methods:
- Behavioral tests in mice (elevated plus maze, hole-board test, pentobarbital-induced hypnosis, picrotoxin-induced seizures).
- Sleep stage analysis in rats.
- Assessment of adenosine levels and adenosine deaminase activity.
- Pharmacological antagonism of adenosine A2a receptors.
Main Results:
- WS0701 exhibited anxiolytic effects in mice, reducing locomotor activity and enhancing pentobarbital-induced hypnosis.
- In rats, WS0701 induced sedation, prolonged non-rapid-eye-movement sleep (NREM), particularly slow-wave sleep (SWS), and reduced rapid-eye-movement sleep (REMS).
- The effects of WS0701 were attenuated by an adenosine A2a receptor antagonist and were associated with increased brain adenosine levels.
Conclusions:
- WS0701 possesses anxiolytic, sedative, and sleep-altering properties.
- These effects are likely mediated through modulation of the adenosine system.
- WS0701 represents a potential therapeutic agent for sleep and anxiety disorders.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:20Sedatives and Hypnotics Drugs: Barbiturates
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
01:19Management of Insomnia